menu
    • menu
    [{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hydrogen Peroxide","moa":"||IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"DMT310","moa":"||IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"DMT310","moa":"||IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Kortuc","sponsor":"AXA Japan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Hydrogen Peroxide","moa":"Free radical","graph1":"Oncology","graph2":"Phase II","graph3":"Kortuc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Kortuc \/ AXA Japan","highestDevelopmentStatusID":"8","companyTruncated":"Kortuc \/ AXA Japan"}]

    Find Clinical Drug Pipeline Developments & Deals for Hydrogen Peroxide (H2O2)

    Menu

    Hydrogen Peroxide (H2O2)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dermata Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Dermata Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DMT310,Hydrogen Peroxide

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $2.5 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Dermata Therapeutics Announces Closing of $2.55 Million Private Placement

                            Details : The net proceeds will used to support the company's late-stage product Exyngari (DMT310). It is being evaluated for the treatment of Acne Vulgaris.

                            Product Name : Xyngari

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 23, 2025

                            Lead Product(s) : DMT310,Hydrogen Peroxide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $2.5 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dermata Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Dermata Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DMT310,Hydrogen Peroxide

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $2.5 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Dermata Therapeutics Announces $2.55M Private Placement Priced At-The-Market

                            Details : The net proceeds will used to support the company's late-stage product Exyngari (DMT310). It is being evaluated for the treatment of Acne Vulgaris.

                            Product Name : Xyngari

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 22, 2025

                            Lead Product(s) : DMT310,Hydrogen Peroxide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $2.5 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Dermata Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Dermata Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xyngari,Hydrogen Peroxide

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 Based on Agreemen...

                            Details : DMT310 is a novel, once-weekly, topical product candidate derived from a freshwater sponge being developed for the treatment of multiple skin diseases like Acne Vulgaris.

                            Product Name : DMT310

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 16, 2023

                            Lead Product(s) : Xyngari,Hydrogen Peroxide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kortuc

                            Japan arrow
                            Cophex
                            Not Confirmed

                            Kortuc

                            Japan arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydrogen Peroxide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : AXA Japan

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            KORTUC Inc. Closes Financing from AXA Japan

                            Details : KORTUC will use the financing to fund Research and Development activities, accelerate its Pivotal Phase II Study on a Hydrogen Peroxide candidate in the UK and pursue additional Pivotal Studies in the US.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 29, 2021

                            Lead Product(s) : Hydrogen Peroxide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : AXA Japan

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth